These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 988636)

  • 1. Minimal brain dysfunction:dopamine depletion?
    Science; 1976 Oct; 194(4263):450-3. PubMed ID: 988636
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction.
    Shaywitz BA; Yager RD; Klopper JH
    Science; 1976 Jan; 191(4224):305-8. PubMed ID: 942800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catecholamines and attention. I: Animal and clinical studies.
    Clark CR; Geffen GM; Geffen LB
    Neurosci Biobehav Rev; 1987; 11(4):341-52. PubMed ID: 3325864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemispheric processing and methylphenidate effects in attention-deficit hyperactivity disorder.
    Malone MA; Kershner JR; Swanson JM
    J Child Neurol; 1994 Apr; 9(2):181-9. PubMed ID: 8006372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of stimulants in attention-deficit/hyperactivity disorder.
    Stahl SM
    J Clin Psychiatry; 2010 Jan; 71(1):12-3. PubMed ID: 20129003
    [No Abstract]   [Full Text] [Related]  

  • 6. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
    Prince J
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder.
    Del Campo N; Chamberlain SR; Sahakian BJ; Robbins TW
    Biol Psychiatry; 2011 Jun; 69(12):e145-57. PubMed ID: 21550021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tyrosine on attention deficit disorder with hyperactivity.
    Eisenberg J; Asnis GM; van Praag HM; Vela RM
    J Clin Psychiatry; 1988 May; 49(5):193-5. PubMed ID: 3284877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.
    Arnsten AF
    J Clin Psychiatry; 2006; 67 Suppl 8():7-12. PubMed ID: 16961424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neurotransmission in developmental disorders].
    Takeuchi Y
    No To Hattatsu; 2008 Nov; 40(6):451-5. PubMed ID: 19039985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of serotonin-norepinephrine reuptake inhibitors on locomotion and prefrontal monoamine release in spontaneously hypertensive rats.
    Umehara M; Ago Y; Fujita K; Hiramatsu N; Takuma K; Matsuda T
    Eur J Pharmacol; 2013 Feb; 702(1-3):250-7. PubMed ID: 23376565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: focus on catecholamine receptor pharmacology.
    Shenker A
    Adv Pediatr; 1992; 39():337-82. PubMed ID: 1359740
    [No Abstract]   [Full Text] [Related]  

  • 13. The neuropsychopharmacology of attention-deficit/hyperactivity disorder.
    Pliszka SR
    Biol Psychiatry; 2005 Jun; 57(11):1385-90. PubMed ID: 15950012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing comorbidity in adults with attention-deficit/hyperactivity disorder.
    Hornig M
    J Clin Psychiatry; 1998; 59 Suppl 7():69-75. PubMed ID: 9680055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lisdexamfetamine dimesylate.
    Elia J; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 May; 6(5):343-4. PubMed ID: 17539056
    [No Abstract]   [Full Text] [Related]  

  • 16. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses.
    Genro JP; Kieling C; Rohde LA; Hutz MH
    Expert Rev Neurother; 2010 Apr; 10(4):587-601. PubMed ID: 20367210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attention-Deficit/Hyperactivity Disorder.
    Bokor G; Anderson PD
    J Pharm Pract; 2014 Aug; 27(4):336-49. PubMed ID: 25092688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting Impulsivity: Brain Mechanisms and Neuropsychiatric Implications.
    Robbins TW; Dalley JW
    Nebr Symp Motiv; 2017; 64():201-226. PubMed ID: 30351564
    [No Abstract]   [Full Text] [Related]  

  • 19. The dopaminergic hypothesis of attention-deficit/hyperactivity disorder needs re-examining.
    Gonon F
    Trends Neurosci; 2009 Jan; 32(1):2-8. PubMed ID: 18986716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug policy and treatment bias due to the dopamine-deficit theory of child attention-deficit hyperactivity disorder.
    Rastmanesh R
    Atten Defic Hyperact Disord; 2010 Nov; 2(3):149-57. PubMed ID: 21432601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.